Search Result

Results for "

NACHT domain

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (3) Autophagy (1) Caspase (6) CDK (2) COX (1) Cytochrome P450 (2) Interleukin Related (8) NF-κB (3) NO Synthase (1) NOD-like Receptor (NLR) (14) p38 MAPK (2) PI3K (2) Reference Standards (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (1) Inflammation/Immunology (13) Metabolic Disease (2) Neurological Disease (2)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: Discoidin Domain Receptor Epigenetic Reader Domain EHD Protein WDR5 YTHDF PASK/STK37 VISTA SHP1 PIKfyve BCL6 PNPLA3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103666

CY-09 Maximum Cited Publications 50 Publications Verification	NOD-like Receptor (NLR)	Inflammation/Immunology
CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation .

HY-N1431

Tabersonine 3 Publications Verification	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK	Inflammation/Immunology Cancer
Tabersonine is a selective, orally active NLRP3 inhibitor. Tabersonine directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer .

HY-162333

BAL-0028	NOD-like Receptor (NLR) Interleukin Related	Inflammation/Immunology
BAL-0028 is a reversible inhibitor of NLRP3 activation with an IC₅₀ value of 25 nM. BAL-0028 binds closely to the NACHT domain of the NLRP3 with K_D values of 104-123 nM. BAL-0028 can inhibit the secretion of IL-1β and has anti-inflammatory activity .

HY-N6893

Ergolide 3 Publications Verification	NF-κB NOD-like Receptor (NLR) Apoptosis Autophagy	Neurological Disease Cancer
Ergolide is an orally active dual inhibitor targeting NF-κB/p65 and NLRP3. Ergolide blocks the NF-κB signaling pathway and the nuclear translocation of p65, and irreversibly binds to the *NACHT* domain of NLRP3 to inhibit inflammasome assembly. Ergolide significantly reduces the production of inflammatory mediators (e.g., NO, PGE₂) and cytokines, induces cancer cell apoptosis, autophagy and ROS generation. Ergolide also enhances the anti-tumor effect of vincristine. Ergolide alleviates acute lung injury via an NLRP3-dependent mechanism, and effectively improves the survival rate and behavioral function of septic mice and inflammatory zebrafish models. Ergolide is used in the research of metastatic uveal melanoma, neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease), sepsis and acute lymphoblastic leukemia .

HY-149604

NLRP3-IN-21 1 Publications Verification	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-21 (compound L38) is a NLRP3 inflammasome inhibitor with inflammatory properties. NLRP3-IN-21 inhibits NLRP3 inflammasome activation and pyroptosis by suppressing gasdermin D cleavage, ASC oligomerization, and NLRP3 inflammasome assembly .

HY-N1431A

Tabersonine hydrochloride 3 Publications Verification	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK	Neurological Disease Inflammation/Immunology
Tabersonine hydrochloride is a selective, orally active NLRP3 inhibitor. Tabersonine hydrochloride directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine hydrochloride also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine hydrochloride can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine hydrochloride is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer .

HY-179024

NP3-742	NOD-like Receptor (NLR) Interleukin Related	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
NP3-742 is an orally active NLRP3 inhibitor that binds to the NLRP3 NACHT domain. NP3-742 inhibits IL-1β release with IC₅₀s of 6 nM and 47 nM in both the cellular and whole blood assays, respectively. NP3-742 is highly selective against a panel of more than 50 enzymes, receptors and sodium and calcium channels. NP3-742 can be used for the study of gout, cardiovascular disease or osteoarthritis .

HY-145087

NP3-146 NLRP3-IN-5	NOD-like Receptor (NLR) Interleukin Related Caspase	Inflammation/Immunology
NP3-146 is a NLRP3 inflammasome inhibitor through locking the NACHT domain of NLRP3. NP3-146 shows potent inhibitory activity against IL-1β release with an IC₅₀ value of 0.171 μM in LPS (HY-D1056)/Nigericin (HY-127019)-stimulated BMDM cells. NP3-146 regulates the levels of cleaved Caspase-1 and cleaved IL-1β in cell supernatants. NP3-146 can be used for the research of inflammatory diseases .

HY-172134

NLRP3-IN-70	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-70 (Compound 5m) is an NLRP3 inflammasome inhibitor with low oral bioavailability. NLRP3-IN-70 can directly bind to the *NACHT* domain of the NLRP3 protein and block the interaction of NLRP3 and ASC, thus inhibiting ASC oligomerization and NLRP3 inflammasome assembly. NLRP3-IN-70 can be used in the research of sepsis and nonalcoholic steatohepatitis .

HY-145087A

NP3-146 sodium	NOD-like Receptor (NLR) Interleukin Related Caspase	Inflammation/Immunology
NP3-146 sodium is a NLRP3 inflammasome inhibitor through locking the NACHT domain of NLRP3. NP3-146 sodium shows potent inhibitory activity against IL-1β release with an IC₅₀ value of 0.171 μM in LPS (HY-D1056)/Nigericin (HY-127019)-stimulated BMDM cells. NP3-146 sodium regulates the levels of cleaved Caspase-1 and cleaved IL-1β in cell supernatants. NP3-146 sodium can be used for the research of inflammatory diseases .

HY-182778

Anti-inflammatory agent 114	NOD-like Receptor (NLR) COX NO Synthase	Inflammation/Immunology
Anti-inflammatory agent 114 is an anti-inflammatory agent. Anti-inflammatory agent 114 binds to the allosteric inhibitory pocket in the NLRP3 NACHT domain. Anti-inflammatory agent 114 inhibits the expression of iNOS, COX-2 and NLRP3. Anti-inflammatory agent 114 can be used for the research of inflammatory diseases .

HY-183296

NLRP3-IN-91	NOD-like Receptor (NLR) Interleukin Related Caspase	Inflammation/Immunology
NLRP3-IN-91 is a potent NLRP3 inflammasome inhibitor with a K_d of 558.4 nM. NLRP3-IN-91 directly targets the NLRP3 NACHT domain, blocks inflammasome assembly and activation, and exerts anti-inflammatory effects. NLRP3-IN-91 increases survival time in a murine model of LPS (HY-D1056)-induced sepsis. NLRP3-IN-91 can be used for the research of sepsis .

HY-181488

NLRP3-IN-87	NOD-like Receptor (NLR) Caspase Interleukin Related	Metabolic Disease Inflammation/Immunology
NLRP3-IN-87 is a selective and orally active NLRP3 inhibitor with a K_d of 0.23 μM. NLRP3-IN-87 binds directly to the NLRP3 NACHT domain, disrupts NLRP3-NEK7 and NLRP3-ASC interactions, inhibits ASC oligomerization, and blocks inflammasome assembly. NLRP3-IN-87 suppresses caspase-1 activation and IL-1β secretion. NLRP3-IN-87 exhibits anti-inflammatory and analgesic activity, reducing joint swelling, inflammation, and pain in an MSU (HY-B2130A)-induced acute gout mouse model. NLRP3-IN-87 can be used for the research of gout .

HY-103666R

CY-09 (Standard)	Reference Standards NOD-like Receptor (NLR)	Inflammation/Immunology
CY-09 (Standard) is the analytical standard of CY-09 (HY-103666). This product is intended for research and analytical applications. CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1431

Tabersonine 3 Publications Verification	Apocynaceae Alkaloids Structural Classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK
Tabersonine is a selective, orally active NLRP3 inhibitor. Tabersonine directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer .

HY-N6893

Ergolide 3 Publications Verification	Phyllodium pulchellum (L.) Desv. Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Plants Compositae Inflammation/Immunology Disease Research Fields Piptanthus nepalensis (Hook.) D. Don Source Classification	NF-κB NOD-like Receptor (NLR) Apoptosis Autophagy
Ergolide is an orally active dual inhibitor targeting NF-κB/p65 and NLRP3. Ergolide blocks the NF-κB signaling pathway and the nuclear translocation of p65, and irreversibly binds to the *NACHT* domain of NLRP3 to inhibit inflammasome assembly. Ergolide significantly reduces the production of inflammatory mediators (e.g., NO, PGE₂) and cytokines, induces cancer cell apoptosis, autophagy and ROS generation. Ergolide also enhances the anti-tumor effect of vincristine. Ergolide alleviates acute lung injury via an NLRP3-dependent mechanism, and effectively improves the survival rate and behavioral function of septic mice and inflammatory zebrafish models. Ergolide is used in the research of metastatic uveal melanoma, neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease), sepsis and acute lymphoblastic leukemia .

HY-N1431A

Tabersonine hydrochloride 3 Publications Verification	Apocynaceae Alkaloids Plants Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK
Tabersonine hydrochloride is a selective, orally active NLRP3 inhibitor. Tabersonine hydrochloride directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine hydrochloride also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine hydrochloride can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine hydrochloride is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer .

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702188

	NLRP1 Protein, Human NLRP1; NACHT; LRR and PYD domains-containing protein 1; Caspase recruitment domain-containing protein 7; Death effector filament-forming ced-4-like apoptosis protein; Nucleotide-binding domain and caspase recruitment domain	Human	E. coli
	The NLRP1 protein is a key sensor in the NLRP1 inflammasome and can trigger pyroptosis in response to multiple pathogen-related signals. It acts as a pattern recognition receptor (PRR), recognizes pathogens and damage-related signals, and initiates inflammasome complex formation and CASP1 activation. NLRP1 Protein, Human is the recombinant human-derived NLRP1 protein, expressed by E. coli , with tag free.

HY-P702189

	NLRP1 Protein, Human (His) NLRP1; NACHT; LRR and PYD domains-containing protein 1; Caspase recruitment domain-containing protein 7; Death effector filament-forming ced-4-like apoptosis protein; Nucleotide-binding domain and caspase recruitment domain	Human	E. coli
	The NLRP1 protein is a key sensor in the NLRP1 inflammasome and can trigger pyroptosis in response to multiple pathogen-related signals. It acts as a pattern recognition receptor (PRR), recognizes pathogens and damage-related signals, and initiates inflammasome complex formation and CASP1 activation. NLRP1 Protein, Human (His) is the recombinant human-derived NLRP1 protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87287

	Phospho-NLRC4 (S533) Antibody (YA6970) and NACHT-containing protein antibody; CARD 12 antibody; CARD antibody; CARD LRR and NACHT containing protein 1 antibody; CARD LRR and NACHT containing protein antibody; CARD12 antibody; Caspase recruitment domain containing protein 12 antibody; Caspase recruitment domain family member 12 antibody; Caspase recruitment domain-containing protein 12 antibody; CLAN 1 antibody	WB, ICC/IF	Human, Mouse
	Phospho-NLRC4 (S533) Antibody (YA6970) is a Rat-derived and non-conjugated IgG2b monoclonal antibody, targeting to Phospho-NLRC4 (S533).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

NACHT domain

Inhibitors & Agonists

NaturalProducts

Recombinant Proteins

Antibodies

Natural
Products